A Phase 2 interventional study of Dasatinib and quercetin in Schizophrenia, Treatment Resistant Depression and Aging, Premature, sponsored by Washington University School of Medicine. Active, not recruiting at 1 site in United States. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2026-04-21.
Sponsored by Washington University School of Medicine · Phase 2, Interventional, and Prevention
This pilot open-label study examines the effects of a combination of dasatinib plus quercetin - two drugs that have known senolytics properties - on physiological aging in older individuals with depression or schizophrenia.
This is a pilot study that will enroll up to 40 participants and will examine the following:
This study will also combine the treatment of dasatinib plus quercetin and lifestyle-based risk factor management - which will involve the research team during the medication intervention portion to provide lifestyle education focusing on strength, balance, and nutrition. The research team will maintain close contact with participants to offer encouragement, address questions and help navigate barriers to engaging in the activities.
Before study enrollment, participants will be screened using questionnaires and a phone screen prior to being consented.
The participant will be involved for about 1 year and self-administer 8 total doses of the medications - two consecutive days of dasatinib 100mg orally plus quercetin 1250mg orally on weeks 1 (ie., 2 days on, 5 days off), 2, 3, and 4.
The participant will undergo an MRI scan at baseline and approximately week 10 of the study.
Blood draws will occur at baseline, week 1, 2, 3, 4, 10, and at the endpoint. 10 ml of blood will be taken each time for 700 ml over 1 year.
Participants will have several questionnaires and assessments to complete at baseline, week 10, and the study's endpoint.
3,472 studies on the registry are indexed under Schizophrenia; 472 are open to participants now.
This study's planned enrollment of 40 is below the median of 70 across 2,873 interventional studies indexed under Schizophrenia.
Browse Schizophrenia studies →Washington University School of Medicine is the lead sponsor of 1,764 studies on the registry; 270 are open to participants now.
Of its 325 completed or terminated interventional studies of FDA-regulated products, 212 (65%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
open label dasatinib plus quercetin combined as a drug therapy
Drug: Dasatinib · Drug: quercetin
dasatinib 100mg The intervention will involve the participant taking dasatinib 100mg and quercetin 1250ng combined.
Also known as: sprycel, sophoretin
The intervention will involve the participant taking dasatinib 100mg and quercetin 1250ng combined.
Also known as: quercetine, Vitamine P
Number of participants who successfully completed and safely tolerated the intervention
Test the safety and feasibility of dasatinib plus quercetin
Time frame: 10 weeks
Plan to share: Yes — Deidentified data available upon request
Supporting information: Study protocol, Sap, Icf
This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Washington University School of Medicine